Stefan Kreuzer, MD
Orthopaedic Surgery · Houston, TXNPI 1780683540
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $5,799,287 of the $6,156,631 with a category attached, or 94.2%. Stryker accounts for 79.9% of it on its own, with 32 other manufacturers making up the rest. Among orthopaedic surgery clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 379 payments — averaging $16,244 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$4.9M
- Omnilife Science, Inc$982K
- Think Surgical, Inc.$123K
- UOC USA Inc$29K
- Naviswiss, Inc.$28K
- Corin USA$22K
- plus $51K from 27 others
Across 42 payments — averaging $3989.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Smith+Nephew$81K
- Think Surgical, Inc.$32K
- Medical Device Business Services, Inc.$22K
- Omnilife Science, Inc$21K
- Corin USA$11K
Across 9 payments — averaging $78,809 each. An ownership or investment interest held by the physician or an immediate family member.
- Omnilife Science, Inc$440K
- Naviswiss, Inc.$269K
- Corin USA$0
- Orthosensor Inc.$0
What the payments were for
- Royalty or licence$5,799,28794%
- Consulting fees$306,0455%
- Speaking & faculty fees$6,6700%
- Travel & lodging$30,0540%
- Food & beverage$14,5750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 29 | $4,921,597 |
| Omnilife Science, Inc | 116 | $981,984 |
| Think Surgical, Inc. | 50 | $122,683 |
| UOC USA Inc | 14 | $29,283 |
| Naviswiss, Inc. | 28 | $28,299 |
| Corin USA | 23 | $22,227 |
| Bodycad USA Corp | 9 | $15,067 |
| Conformis, Inc. | 28 | $13,873 |
| Intellijoint Surgical Inc. | 5 | $10,305 |
| Restor3d, Inc. | 4 | $5,816 |
| Smith+Nephew | 8 | $1,836 |
| Arthrex | 7 | $1,047 |
| Zimmer Biomet | 7 | $587 |
| Pacira Pharmaceuticals Incorporated | 12 | $429 |
| Davol Inc. | 2 | $277 |
| Medtronic | 3 | $181 |
| Microport Orthopedics Inc | 1 | $173 |
| Steris Corporation | 1 | $122 |
| Acelrx Pharmaceuticals, Inc. | 1 | $120 |
| Ferring Pharmaceuticals Inc. | 7 | $115 |
| Medacta USA, Inc. | 1 | $103 |
| Encore Medical, LP | 1 | $101 |
| Bioventus LLC | 4 | $64 |
| Johnson & Johnson | 4 | $63 |
| Vertex | 2 | $54 |
| Heron Therapeutics, Inc. | 3 | $53 |
| Baudax Bio Inc. | 2 | $38 |
| Nalu Medical, Inc. | 2 | $27 |
| KCI USA, Inc. | 1 | $27 |
| ERMI LLC | 1 | $26 |
| Pacira Therapeutics, Inc. | 1 | $20 |
| Coopersurgical, Inc. | 1 | $19 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAKO$4,921,597
- Unity$266,159
- UNITY TOTAL KNEE SYSTEM$147,448
- OMNIBotics 3.0$127,362
- Tsolution One Surgical System$121,213
- Naviswiss Knee Navigation$20,786
- OMNIBotics v 2.7$19,275
- Various Products$17,510
- U2, PSA, UTS, UTF, CONFORMITY, U-MOTION II, U-STAR II$14,400
- CONFORMITY, U2$13,680
- Identity Imprint Knee Replacement System$11,780
- Corin Technology$11,600
- Trifit TS$11,282
- Intellijoint HIP$10,272
- Apollo$7,975
- Naviswiss Hip navigation$7,520
- Naviswiss Hip/Knee Navigation$6,078
- REFLEX$5,250
- CORIN TRIFIT CF HIP STEM$4,752
- Corin Hips$3,264
How this compares
$6,156,631 in reported general payments places this provider in the 95th percentile of 1,337 orthopaedic surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 39 | $10,424 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 779 | $8,482 |
| Celecoxib | 145 | $5,306 |
| Ondansetron OdtOndansetron | 557 | $2,887 |
| Gabapentin | 544 | $1,875 |
| Cefadroxil | 498 | $1,819 |
| Meloxicam | 494 | $1,344 |
| Tramadol Hcl | 204 | $696 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 72 | $526 |
| Pregabalin | 24 | $182 |
| Methylprednisolone | 21 | $158 |
| Cephalexin | 15 | $127 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 14 | $105 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 37 | $94 |
| Ibuprofen | 11 | $81 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $63 | $10,42439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,337 orthopaedic surgery providers in Texas.
Other orthopaedic surgery in Houston
- Stephen IncavoHouston$4.3M
- Thomas EdwardsHouston$4.1M
- Adam FreedhandHouston$1.8M
- Jeffrey KozakHouston$1.1M
- Travis HansonHouston$1M
- Thomas TanousHouston$698K
- Alan RechterHouston$605K
- Ugonna IhekweazuHouston$544K
- Darrell HansonHouston$284K
- Stephen BurkhartSan Antonio$185.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.